Verismo's SynKIR-110 and SynKIR-310 are in Phase 1 trials; Cryoport says IntegriCell will support process development, transfer and cryopreservation.

An early report of a new type of CAR T cell therapy, called KIR-CAR, was shared in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.

Verismo Therapeutics showcases new preclinical data for SynKIR™-310 KIR-CAR that indicates enhanced anti-tumor activity and potential in treating B cell malignancies.

Preliminary data from Verismo Therapeutics’ STAR-101 trial of SynKIR™-110 KIR-CAR shows promise in solid tumor treatments, showcasing safety and efficacy.

At the AACR Annual Meeting 2026, Verismo Therapeutics will present promising Phase 1 data on its innovative KIR-CAR therapies, SynKIR™-110 and SynKIR™-310, highlighting advancements in immunotherapy for various cancers.

Verismo Therapeutics presented new preclinical findings on SynKIR™-310, showcasing enhanced tumor control and reduced cytokine release compared to traditional CAR-T therapies.

Verismo Therapeutics has shared groundbreaking preclinical data on SynKIR™-110 during SITC 2025, showcasing its superior efficacy and safety in targeting solid tumors.

Verismo Therapeutics has announced the start of its Phase 1 CELESTIAL-301 trial for SynKIR™-310, targeting relapsed B cell Non-Hodgkin Lymphomas. The trial aims to offer new treatment options for patients facing these challenging cancers.

Verismo Therapeutics announces a strategic investment partnership with IFLI to enhance development of SynKIR™-310 aimed at treating follicular lymphoma.

IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)...

SynKIR™-310 achieved greater tumor control at lower doses with reduced cytokines in vivo, compared to CD19-targeted CAR T cells analogous to tisagenlecleucel. PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR...

PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310....

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's…